SpencerHenickBachowMD

Genitourinary Oncology, Gynecologic Cancer, Hematologic Oncology

Hematologist/Oncologist | Lynn Cancer Institute | Baptist Health South Florida

Overview of Dr. Bachow

Spencer Bachow, M.D., is a medical oncologist and hematologist at the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health. Dr. Bachow specializes in treating hematologic malignancies, non-malignant hematologic disorders, genitourinary cancers and gynecologic cancers. He is also the medical director of the Center for Hematology-Oncology laboratory.

He is a member of the Alpha Omega Alpha Honor Medical Society, American Society of Clinical Oncology and American Society of Hematology.

Office
701 NW 13th St
Boca Raton, FL 33486
Book by Phone+1(561) 709-8606

Fax+1 561-955-6618

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2014 - 2017
University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
University of Florida College of MedicineClass of 2011
University of FloridaB.S., Interdisciplinary Studies in Integrative Biology, Summa Cum Laude, 2007

Certifications & Licensure

FL State Medical License 2016 - 2026
NY State Medical License 2014 - 2017
PA State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Faculty Member of the Year Internal Medicine Residency-Hematology/Oncology, FAU Schmidt College of Medicine, 2020
J. Robert Cade, M.D. Memorial Award UF College of Medicine, 2011
Excellence Award in Clinical Psychiatry, Psychiatry Clerkship UF College of Medicine, 2010
Alpha Omega Alpha Honor Medical Society, Junior Year University of Florida College of Medicine, 2010
Gold Humanism Honor Society, The Chapman Chapter, The Arnold P. Gold Foundation 2010
Pre-Doctoral Intramural Research Training Award National Institutes of Health, 2009
Summer Internship in Biomedical Research Award National Institutes of Health, 2008
College of Liberal Arts and Sciences Four-Year Scholar (Salutatorian Group) University of Florida, 2007
Anderson Scholar with High Distinction University of Florida, 2005
University Scholar University of Florida, 2005
Golden Key International Honor Society 2004
Honor Society of Phi Kappa Phi 2004
Florida Bright Futures Scholarship 2003
Honors Program University of Florida, 2003
Join now to see all

Clinical Trials

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma Start of enrollment: 2012 Dec 01
Completed
Phase 1, Phase 2
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
Recruiting
Phase 3
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer Start of enrollment: 2017 Mar 24
Active, not recruiting
Phase 3
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC Start of enrollment: 2020 Jul 24
Terminated
Phase 2
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis Start of enrollment: 2020 Sep 29
Active, not recruiting
Phase 3
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2021 Mar 09
Active, not recruiting
Phase 3
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial Start of enrollment: 2021 Jan 19
Terminated
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2021 Jun 18
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

317 citations
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander
Haematologica. 2018-05-01
159 citations
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill
Blood. 2016-11-03
What appears safe is sometimes not: a reason for caution.
Spencer Henick Bachow, Nicole Lamanna
Blood. 2016-05-19

Journal Articles

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
Mato AR., Hill BT., Lamanna N., Barr PM., Ujjani CS., Brander DM., Howlett C., Skarbnik AP., Cheson BD., Zent CS., Pu JJ., Kiselev P., Foon K., Lenhart J., Bachow SH.,..., Annals of Oncology, 1/1/2017
Emerging Therapies in Relapsed/Refractory Peripheral T-Cell Lymphoma
Bachow SH, O�Connor OA, Clinical Advances in Hematology and Oncology, 1/1/2015
Vitamin D and Cancer�A Review
Friedman C.F. and Bachow SH, US Endocrinology, 1/1/2013

Abstracts/Posters

Peripheral Blood Smear Basics.
Bachow, S., Resident Report, FAU Schmidt College of Medicine Internal Medicine Residency Program, Delray Beach, FL, 1/1/2018
Acute Myeloid Leukemia.
Bachow, S., Pathophysiology and Therapeutics, Second Year Medical School Curriculum, FAU Schmidt College of Medicine, Boca Raton, FL, 1/1/2018
Thrombocytopenia in Hospitalized Patients.
Bachow, S., Medical Grand Rounds, FAU Schmidt College of Medicine, Boca Raton Regional Hospital, Boca Raton, FL, 1/1/2018
Common Hematology and Oncology Emergencies and Issues.
Bachow, S., Internal Medicine Residency Core Curriculum, FAU Schmidt College of Medicine, Boca Raton, FL, 1/1/2018
Bleeding and Clotting for Surgeons.
Bachow, S., General Surgery Residency Core Curriculum, FAU Schmidt College of Medicine, Boca Raton, FL, 1/1/2018
Warm Autoimmune Hemolytic Anemia.
Bachow, S., Resident Report, FAU Schmidt College of Medicine Internal Medicine Residency Program, Delray Beach, FL, 1/1/2017
Outcomes of CLL Patients Treated with Targeted Agents, Chemoimmunotherapy, and next steps with combination therapy.
Bachow, S., Grand Rounds, Division of Hematology/Oncology, Columbia University College of Physicians and Surgeons, New York, NY, 1/1/2017
Cancer Genetics.
Bachow, S., Advanced Nurse Practitioner Curriculum, Columbia University School of Nursing, 2015, 2017, 1/1/2017
Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients.
Mato A., Lamanna N., Ujjani C., Brander D., Hill B., Howlett C., Skarbnik A., Cheson B., Zent C., Nabhan C., Pu J., Kiselev P., Bachow S., Winter A., Cruz A., Claxton ..., American Society of Hematology Annual Meeting, San Diego, CA, 1/1/2016
Characteristics and Outcomes in Women and Men in the Connect CLL Registry.
Bachow S., Nabhan C., Mato A., Flowers C., Kay N., Grinblatt D. L, Davids M., Weiss M., Sullivan K., Flick E. D., Kiselev P., Bhushan S., Swern A., Sharman J. P., Lama..., Society of Hematologic Oncology Annual Meeting, Houston, TX, 1/1/2016
Real World Outcomes of CLL Patients Treated with Sequential Kinase Inhibitors.
Bachow, S., Grand Rounds, Division of Hematology/Oncology, Columbia University College of Physicians and Surgeons, New York, NY, 1/1/2016
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients.
Mato A., Hill B., Lamanna N., Barr P., Ujjani C., Brander D., Howlett C., Skarbnik A., Cheson B., Zent C., Nabhan C., Pu J., Kiselev P., Bachow S., Winter A., Cruz A.,..., American Society of Hematology Annual Meeting, San Diego, CA, 1/1/2016
Fertility Preservation for Inpatient Males Undergoing Their First Chemotherapy for Hematologic Malignancies.
Bachow, S., Grigg C., Ingham M., Kalac M., Lee D., 1st Annual Oncology Quality Symposium, Columbia University College of Physicians and Surgeons, New York, NY, 1/1/2016
Favorable Outcomes in CLL Patients with Alternate Kinase Inhibitors Following Ibrutinib or Idelalsib Discontinuation: Results from a Large Multi-Center Study.
Mato A., Nabhan C., Barr P., Ujjani C., Hill B., Lamanna N., Skarbnik Al, Howlett C., Pu J., Sehgal A., Strelec L., Vandegrift A., Rago A., Zent C., Feldman T., Goy A...., Society of Hematology Annual Meeting, Orlando, FL, 1/1/2015
Aspiration Pneumonia: Deadly, Costly & Preventable (Often).
Bachow S., Ahya V., Dubin R., Department of Medicine Grand Rounds, Perelman School of Medicine, University of Pennsylvania, 1/1/2014
Trial in progress: Prognostic factors in patients with advanced bladder cancer 'unflit' for cisplatin-based chemotherapy.
Sedrak M., Bachow S., Gunnarson O., Pfanzelter N., Vaughn D., Mamtani R., Keefe S, Department of Medicine Research Day, University of Pennsylvania, Philadelphia, PA, 1/1/2013
Study in progress: What are the factors that are precluding cisplatin-eligible patients with muscle-invasive urothelial carcinoma from receiving neoadjuvant chemotherapy?
Bachow S., Sedrak M., Gunnarson O., Pfanzelter N., Vaughn D., Guzzo T., Malkowicz B., Mamtani R., Keefe S., Department of Medicine Research Day, University of Pennsylvania, Philadelphia, PA, 1/1/2013
The GLUT4 Hub: New evidence of a transition site at the plasma membrane involved in GLUT4 recycling.
Bachow S., Stenkula K., Lizunov V., Cushman S., NIH Poster Day, National Institutes of Health, Bethesda, MD, 1/1/2009
GLUT4 trafficking and fusion visualized by fluorescent microscopy of plasma membrane lawns from rat adipocytes.
Bachow S., Stenkula K., Yver D., Cushman S., College of Medicine Research Day; Poster Day, National Institutes of Health, Bethesda, MD, 2008; University of Florida College of Medicine, Gainesville, FL, 2009, 1/1/2009
Peripheral myelin protein 22 modulates the cytoskeletal organization of epithelia and Schwann cells.
Amici S., Bachow S., Notterpek L, Florida Genetics Conference, Gainesville, FL, 1/1/2006
Peripheral myelin protein 22 and its effects on the epithelial cytoskeleton.
Bachow, S., University Scholars Symposium, University of Florida, Gainesville, FL, 1/1/2006
Join now to see all

Lectures

Bringing the Patient into the Equation: A Pilot CME Initiative on the Treatment of Acute Myeloid Leukemia.
Research to Practice. Video Program. Miami, Florida. - 3/2021
Bachow, S. Myeloid Neoplasms. Pathophysiology and Therapeutics. Second Year Medical School Curriculum. FAU Schmidt College of Medicine. Boca Raton, Florida.
2021
Bachow, S. Myeloid Neoplasms. Pathophysiology and Therapeutics. Second Year Medical School Curriculum. FAU Schmidt College of Medicine. Boca Raton, Florida.
2020
Bachow, S. Myeloid Neoplasms. Pathophysiology and Therapeutics. Second Year Medical School Curriculum. FAU Schmidt College of Medicine. Boca Raton, Florida.
2020
Bachow, S. Common Hematology and Oncology Emergencies and Issues. Internal Medicine Residency Core Curriculum. FAU Schmidt College of Medicine. Boca Raton, Florida.
2020
Hematology and Oncology Acute Issues.
FAU Schmidt College of Medicine, Boca Raton, FL - 1/1/2018
Join now to see all

Other

Overexpression of peripheral myelin protein 22 modifies the cytoskeleton of epithelia and is associated with alterations in cell adhesion and migration. (Senior Thesis)
Bachow, S.
University of Florida, Gainesville, FL - 1/1/2007